CD5

Vittoria Therapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Tuesday, February 27, 2024

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced today that accomplished life sciences leader, Rosemary Mazanet, M.D., Ph.D., has joined the Company as Chief Medical Officer.

Key Points: 
  • PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced today that accomplished life sciences leader, Rosemary Mazanet, M.D., Ph.D., has joined the Company as Chief Medical Officer.
  • “Drawing on her extensive expertise in the oncology and hematology drug development ecosystem, Dr. Mazanet will be an invaluable asset to Vittoria’s executive team as we enter first-in-human studies for our lead program,” said Nicholas Siciliano, Ph.D., Vittoria’s Chief Executive Officer.
  • Vittoria’s innovative approach to CAR-T development could change the treatment paradigm for T-cell lymphoma patients struggling with this debilitating disease.
  • Dr. Mazanet received her clinical training in internal medicine and oncology at Harvard Hospitals.

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

Retrieved on: 
Thursday, December 7, 2023

PHILADELPHIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.

Key Points: 
  • PHILADELPHIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.
  • “The FDA clearance of our investigational new drug application for VIPER-101 marks a pivotal milestone for Vittoria Biotherapeutics and our mission to transform therapeutic outcomes for patients battling difficult to treat diseases,” said Dr. Nicholas Siciliano, Ph.D., chief executive officer of Vittoria.
  • VIPER-101 is uniquely engineered to both avoid fratricide and unlock the benefit of circumventing the inhibitory CD5 signaling pathway.
  • Engineered using a proprietary five-day process to preserve cell stemness, the features of VIPER-101 synergize to maximize potency, safety, and manufacturing efficiency.

Vittoria Biotherapeutics Announces the Presentation of New Data Supporting the Company's Platform at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Wednesday, November 29, 2023

PHILADELPHIA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics announced the presentations of abstracts authored by researchers at the University of Pennsylvania and a poster authored by the Company, at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, taking place from December 9-12th, 2023, in San Diego, California.

Key Points: 
  • PHILADELPHIA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics announced the presentations of abstracts authored by researchers at the University of Pennsylvania and a poster authored by the Company, at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, taking place from December 9-12th, 2023, in San Diego, California.
  • The oral presentations will include recent data generated at Penn with the Company’s Senza5™ platform, a technology exclusively licensed from Penn to Vittoria, along with additional pipeline technologies.
  • By harnessing the fundamental biology of T cells, Senza5 is designed to engineer cell therapies with improved anti-tumor efficacy, stemness, potency, and durability through gene-edited CD5 knockout and a proprietary five-day manufacturing process.
  • Oral and poster presentation abstracts to be presented at the meeting can be found below:

Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting

Retrieved on: 
Tuesday, November 14, 2023

AMP’s annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics.

Key Points: 
  • AMP’s annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics.
  • The presenters will share data on OGM’s performance in this research application as compared to traditional cytogenetic methods of analysis, including microarrays.
  • Ryall, Dubuc and Crocker presenting clinical research data generated using OGM across different types of hematological malignancies.
  • In addition, 19 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.

Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

Retrieved on: 
Tuesday, November 14, 2023

PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.

Key Points: 
  • PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.
  • The funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, an autologous, dual population CD5-knockout CAR-T cell therapy for T-cell Lymphoma, into the clinic.
  • The additional capital will support Vittoria’s clinical development initiatives and advance its next-generation cell therapies that strengthen efficacy, improve safety, and broaden therapeutic applicability for patients with cancer and autoimmune diseases.
  • By acting on the fundamental biology of T cells, Senza5 can be widely utilized to improve the efficacy of engineered T-cell therapies.

Myeloid Therapeutics Announces FDA Fast Track Designation for MT-101 for the Treatment of CD5+ Relapsed/Refractory PTCL

Retrieved on: 
Thursday, October 27, 2022

CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage mRNA-immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MT-101 in patients with refractory or relapsed CD5+ peripheral T cell lymphoma (PTCL). MT-101 is the first mRNA engineered CAR monocyte derived from the Company's proprietary ATAK™ platform delivered with a vein-to-vein time of only 8 days. MT-101 targets CD5, a surface receptor present on greater than 75% of PTCL. The ATAK™ CAR is proprietary to Myeloid and manufactured using the company's patented process. MT-101 has been specifically designed to harness the ability of myeloid cells to penetrate into tumors and promote broad anti-tumor activity.

Key Points: 
  • Food and Drug Administration (FDA) has granted Fast Track Designation to MT-101 in patients with refractory or relapsed CD5+ peripheral T cell lymphoma (PTCL).
  • MT-101 has been specifically designed to harness the ability of myeloid cells to penetrate into tumors and promote broad anti-tumor activity.
  • "We are pleased that MT-101 has received Fast Track designation from the FDA," said Michele Gerber, MD, MPH, Chief Medical Officer of Myeloid.
  • "MT-101 is the first mRNA engineered monocyte cell product to receive Fast Track designation from the FDA, representing a tremendous milestone for Myeloid and the broader field of cell therapy," said Daniel Getts, PhD, CEO of Myeloid.

Cells Expressing T Cell Surface Glycoprotein CD5 Drugs Pipeline Market Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "Cells Expressing T Cell Surface Glycoprotein CD5 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cells Expressing T Cell Surface Glycoprotein CD5 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 or CD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 or CD5) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 or CD5) targeted therapeutics development and features dormant and discontinued projects.

Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans

Retrieved on: 
Wednesday, May 11, 2022

CAMBRIDGE, Mass., May 11, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid", or the "Company"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced the first patient dosed in the IMAGINE Study, a Phase 1/2 clinical study of MT-101, in patients with refractory or relapsed peripheral T cell lymphoma (PTCL), an aggressive form of non-Hodgkin lymphoma. MT-101 is the first mRNA engineered CAR monocyte (CAR-M) derived from the Company's proprietary ATAK™ platform. MT-101 targets CD5, a surface receptor present in many T cell malignancies. The ATAK™ CAR is proprietary to the company and specifically designed to promote broad anti-tumor activity. At Day 28, the primary endpoint for safety and tolerability, the patient had no dose limiting toxicities, no cytokine release syndrome (CRS), and no immune effector cell-associated neurotoxicity syndrome (ICANS).    

Key Points: 
  • MT-101 is the first mRNA engineered CAR monocyte (CAR-M) derived from the Company's proprietary ATAK platform.
  • The ATAKCAR is proprietary to the company and specifically designed to promote broad anti-tumor activity.
  • IMAGINE is a Phase 1/2, multicenter, open-label, dose-escalation and dose cohort expansion clinical trial evaluating MT-101 in patients with refractory or relapsed PTCL.
  • Once Myeloid establishes the recommended Phase 2 dose, a Phase 2 trial will be initiated to support registration in this patient population.

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, February 28, 2022

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced pipeline and business highlights, outlined key 2022 anticipated milestones and reported fourth quarter and full year 2021 financial results.

Key Points: 
  • This is an exciting time for Beam, and Im optimistic about the year ahead as we work to bring potentially life-changing medicines to patients.
  • The collaboration has an initial term of four years and may be extended up to one additional year.
  • This approach could provide a more accessible option for patients, particularly in regions where ex vivo treatment is challenging.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting

Retrieved on: 
Friday, November 12, 2021

In addition, preliminary clinical data from Xencors IL15-Fc program, XmAb306, showed generally good tolerability and robust and sustained immune cell expansion.

Key Points: 
  • In addition, preliminary clinical data from Xencors IL15-Fc program, XmAb306, showed generally good tolerability and robust and sustained immune cell expansion.
  • Xencor engineered PD-L1 x CD28 bispecific antibodies to provide conditional co-stimulation of T cells, activating them when bound to PD-L1+ cells.
  • Anti-tumor activity was significantly enhanced when combined with an anti-PD-1 antibody, compared to either anti-PD-1 or the bispecific antibody alone.
  • Xencor engineered a B7-H3 x NKG2D NKE bispecific antibody with a modified Fc domain to enhance FcR binding.